Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest AMD Stories

2014-02-18 08:27:28

Free AMD Guide Helps Patients Understand Risks, Proactive Measures for Eye Health ST. LOUIS, Feb. 18, 2014 /PRNewswire/ -- February is National AMD/Low Vision Awareness Month. Due to the aging Baby Boomer population, AMD, or Age-related Macular Degeneration, is expected to double by the year 2020, and patient education is critical in fighting vision loss and preserving healthy vision. EyePromise® eye vitamins is offering a complimentary patient education guide, "Getting Clear on...

2014-02-10 23:24:41

Age-Related Macular Degeneration (AMD) is the leading cause of severe vision loss in people over the age of 55 and it roughly affects 15 million Americans. Mechanicsburg, PA (PRWEB) February 10, 2014 Age-Related Macular Degeneration (AMD) is the leading cause of severe vision loss in people over the age of 55 and it roughly affects 15 million Americans. According to the National Eye Institute, AMD occurs when the small central portion of the retina, known as the macula, deteriorates....

2014-02-06 08:29:32

American Academy of Ophthalmology advises that early detection and today's treatments for common eye disease among seniors can help stop vision loss SAN FRANCISCO, Feb. 6, 2014 /PRNewswire/ -- While age-related macular degeneration (AMD) is the leading cause of new cases of blindness in Americans age 65 and older[1], seniors who develop AMD should not consider blindness in advanced age to be inevitable, according to the American Academy of Ophthalmology. During AMD Awareness Month, the...

2014-01-22 08:28:34

Patent Provides Coverage for Lpath's Anti-S1P Antibody in the Treatment of a Wide Variety of Ocular Disorders, Including Wet AMD SAN DIEGO, Jan. 22, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled,...

2014-01-16 20:22:14

Nicox further expands North American diagnostic portfolio with access to the RetnaGene AMD test, a genetic laboratory-developed test to predict the risk of progressing to late-stage or "wet" age-related macular degeneration (AMD) SOPHIA ANTIPOLIS, France and SAN DIEGO, Jan. 16, 2014 /PRNewswire/ -- Nicox S.A. (NYSE Euronext Paris: COX), and Sequenom, Inc. (NASDAQ:SQNM), today announced that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an...

2014-01-13 16:26:26

GENEVA, Jan. 13, 2014 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs announced today that Opthea Pty Ltd has entered into a commercial license agreement with Selexis covering the use of the CHO-M Cell Line and related technologies for the production of OPT-302 (formerly VGX-300), an Fc fusion protein for the treatment of wet Age-Related...

2013-12-23 08:29:31

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, December 23, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Intel Corporation (NASDAQ: INTC), NXP Semiconductors N.V. (NASDAQ: NXPI), Integrated Device Technology, Inc. (NASDAQ: IDTI), Advanced Micro Devices, Inc. (NYSE: AMD), and Freescale Semiconductor, Ltd. (NYSE: FSL). Today's readers may access these reports free of charge - including full...

2013-12-18 23:01:23

Low Vision optometrist and nutritionist John M. Pino O.D., Ph.D., the only International Academy of Low Vision Specialists (IALVS) doctor in Tennessee, holds a doctorate in nutrition. Dr. Pino concurs with a study in the American Journal of Clinical Nutrition suggesting that taking certain B vitamins may prevent Age Related Macular Degeneration (AMD). Lebanon, Tennessee (PRWEB) December 18, 2013 While it’s normal for eyesight to decline over the years, some of the leading causes of...

2013-12-18 08:28:42

TARRYTOWN, N.Y., Dec. 18, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA(®) (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA is ten months from submission, for a target action...

2013-11-26 16:24:25

A "Bionic Eye" for Leading Cause of Blindness in Americans Over Age 65 WASHINGTON, Nov. 26, 2013 /PRNewswire-USNewswire/ -- A tiny device is making a big difference in the lives of people with end-stage macular degeneration (AMD), the leading cause of blindness in people over the age of 65 according to the Centers for Disease Control and Prevention. (Photo: http://photos.prnewswire.com/prnh/20131126/DC19365) "Macular degeneration is a disease of the retina where there is a change...